This study shows a reduction of approximately 25% in the in vivo activity of OCT1/2 in participants with severe stages of liver fibrosis and cirrhosis after achieving sustained virologic response and highlights that OCT1/2 in vivo activity depends on the liver fibrosis stage. The gene discussed is SLC22A1; the disease is Hepatic fibrosis.